- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2018
- Public Summary Document (PSD) November 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2018 PBAC Meeting - Word
Ponatinib – November 2018
Ponatinib: Tablet 15 mg (as hydrochloride), Tablet 45 mg (as hydrochloride); Iclusig®
Last updated
6 March 2019